News for Fulcrum Therapeutics, Inc. (FULC)

We came across a bullish thesis on Cardio Diagnostics Holdings, Inc.(CDIO) on Stock Pursuit’s Substack. In this article, we will summarize the bulls’ thesis on CDIO. Cardio Diagnostics Holdings, Inc. (CDIO)’s share was trading at $4.4 as of 3rd June according to Yahoo Finance. Cardio Diagnostics (CDIO), currently trading below net cash with no long-term debt and […]

Fulcrum Therapeutics (FULC) grants stock options to a new employee as part of its 2022 Inducement Stock Incentive Plan. The company issued 70,000 stock

**media[648057]**

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the ”œCompany”) ( FULC), a clinical-stage biopharmaceutical company focuse

**media[640899]**

Piper Sandler analyst Edward Tenthoff has raised the price target for Fulcrum Therapeutics (FULC) from USD 6.00 to USD 9.00. The new price target represents a s

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the ”œCompany”) ( FULC), a clinical-stage biopharmaceutical company focuse

Fulcrum Therapeutics (FULC) stock gains as Leerink Partners upgrades the stock, citing a favorable risk-reward setup ahead of a key trial readout. Read more here.

In recent developments, Fulcrum Therapeutics (FULC) has seen a significant upgrade in its stock rating by leading analyst firm Leerink Partners. The analyst res

Fulcrum Therapeutics (FULC) has received a significant boost as Cantor Fitzgerald has upgraded its rating on the stock from Neutral to Overweight. This upgrade

Australia-based healthcare business Gelteq Ltd (GELS) is up over 445 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Fulcrum Therapeutics (FULC) grants 96,800 stock options to new employees. Stock options have an exercise price of $2.72, matching the April 7, 2025 clos

**media[592917]**

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the ”œCompany”) ( FULC), a clinical-stage biopharmaceutical company focu

Florida-based Enveric Biosciences, Inc. (ENVB) is up over 155 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Year-End Cash Position: $241 million.Q4 2024 Collaboration Revenue: $0 compared to $900,000 in Q4 2023.Q4 2024 Research and Development Expenses: $11.7 million

Feb 25, 2025 / 01:00PM GMTOperator Good morning and welcome to Fulcrum Therapeutic 4th quarter and full year 2024 financial results and business update conferen

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ETCompany ParticipantsAlex Sapir - President &...

”• On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by th